Document:

Supplemental Stent CSR Agreement

 Exhibit 10.2 
 SUPPLEMENTAL STENT CONTINGENT STOCK RIGHTS AGREEMENT 
 THIS SUPPLEMENTAL STENT CONTINGENT STOCK
RIGHTS AGREEMENT (this “Supplemental Agreement”), dated as of March 23, 2009, is entered into by and among Indevus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Endo Pharmaceuticals Holdings Inc., a
Delaware corporation (“Endo”) and American Stock Transfer & Trust Company, as rights agent (the “Rights Agent”). 
 WHEREAS, the Company and the Rights Agent are parties to a Stent Contingent Stock Right Agreement, dated as of April 17, 2007 (the “CSR Agreement”), pursuant to which the Company and the Rights
Agent made certain agreements with respect to certain contingent stock rights issued by the Company in connection with its acquisition of Valera Pharmaceuticals, Inc. (each such contingent stock right, a “CSR” and collectively, the
“CSRs”). Capitalized terms used herein and not defined herein have the meanings ascribed to such terms in the CSR Agreement; 
 WHEREAS, pursuant to Section 12(b) of the CSR Agreement, upon the merger of the Company with or into another corporation, there shall thereafter be deliverable upon conversion of any CSR in accordance with the terms of the CSR
Agreement the number of shares of stock or other securities, property or cash to which a holder of the number of shares of Indevus Common Stock that would otherwise have been deliverable upon the conversion of such CSR would have been entitled upon
such merger if the Milestone Date had occurred and such CSR had been converted in full immediately prior to such merger; 
 WHEREAS, on
January 5, 2009, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Endo and BTB Purchaser Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Endo,
pursuant to which, among other things, Merger Sub will be merged (the “Merger”) with and into the Company, with the Company continuing as the surviving corporation; 
 WHEREAS, in connection with the transactions contemplated by the Merger Agreement, Endo and American Stock Transfer & Trust Company, as paying
agent, have entered into the Nebido Cash Consideration Agreement and the Octreotide Cash Consideration Agreement, each dated as of February 23, 2009 (respectively, the “Nebido Cash Consideration Agreement” and the
“Octreotide Cash Consideration Agreement”), pursuant to which, upon the occurrence of certain regulatory and commercial milestones, Endo will make certain contingent cash consideration payments to former holders of Indevus Common
Stock; 
 WHEREAS, pursuant to the Merger, the common stock of the Company shall be canceled and converted into the right to receive $4.50
per share, net in cash, plus contractual rights to receive up to (1) $2.00 per share in contingent cash consideration payments pursuant to the Nebido 

 
Cash Consideration Agreement and (2) $1.00 per share in contingent cash consideration payments pursuant to the Octreotide Cash Consideration Agreement;

 WHEREAS, Section 12(c) of the CSR Agreement provides that a successor corporation to the Company shall expressly assume certain
obligations of the Company pursuant to a supplemental contingent stock rights agreement; 
 WHEREAS, pursuant to Section 12(b) of the
CSR Agreement, the board of directors of the Company has determined, in good faith, that the adjustment to the consideration payable pursuant to the CSRs set forth in Section 1.01(b) below is appropriate, which determination has been made in a
duly adopted resolution certified by the Secretary or Assistant Secretary of the Company; 
 WHEREAS, the execution and delivery of this
Supplemental Agreement has been duly authorized by each of the parties hereto and all conditions and requirements necessary to make this Supplemental Agreement a valid and binding agreement have been duly performed and complied with; and 

WHEREAS, pursuant to Section 6.14(a) of the Merger Agreement, this Supplemental Agreement is being executed and delivered prior to the
effectiveness of the Merger. 
 NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, it is mutually covenanted and agreed, for the equal and proportionate benefit of all registered Holders, as follows: 
 ARTICLE 1 
 COVENANTS 

 Section 1.01    Effect of Merger 
 Each of Endo and the Company agree and hereby instruct the Rights Agent that the transactions contemplated by the Merger Agreement, including without limitation, the Merger and the cancellation and conversion of the
Company’s common stock pursuant to Section 3.1(a) of the Merger Agreement, shall be deemed to be a “Reorganization” within the meaning of Section 12(b) of the CSR Agreement. 
  

 2 

 Section 1.02    CSR Consideration 
 Each of Endo and the Company agree and hereby instruct the Rights Agent that, notwithstanding the terms of Section 7(b) of the CSR Agreement and
subject to the other terms of the CSR Agreement, each CSR shall become convertible and shall entitle the Holder thereof, upon satisfaction of the procedures described in Section 8 of the CSR Agreement, after the Milestone Date and until 5:00
p.m., New York City time, on the Termination Date, to receive from Endo or the Company only: 
 (a)    an amount in cash
equal to the product of (x) $4.50 and (y) the quotient of (A) $1.00 divided by (B) the average of the per share closing sale prices of the common stock of the Company as reported by the Nasdaq Global Market for the 10 trading
days ending three trading days prior to the time at which the Merger becomes effective (such time, the “Effective Time”), rounded up to the fourth decimal place (such quotient, the “Exchange Ratio”), 
 (b)    the contractual right, subject to the terms of the Octreotide Cash Consideration Agreement, to receive an amount in cash equal
to the product of (x) $1.00 and (y) the Exchange Ratio, in the case that the Approval Milestone Date (as defined in the Octreotide Cash Consideration Agreement) occurs on or before February 23, 2013, 
 (c)    the contractual right, subject to the terms of the Nebido Cash
Consideration Agreement, to receive an amount in cash equal to the product of (x) $2.00 and (y) the Exchange Ratio, in the case that the Approval with Label Milestone Date (as defined in the NEBIDO® Cash Consideration Agreement) occurs on or before February 23, 2012, 
 (d)    the
contractual right, subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $1.00 and (y) the Exchange Ratio, in the case that the Approval without Label Milestone Date (as
defined in the Nebido Cash Consideration Agreement) occurs on or before February 23, 2012, and 
 (e)    the
contractual right, subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $1.00 and (y) the Exchange Ratio, in the case that the Net Sales Milestone Date (as defined in the
Nebido Cash Consideration Agreement) occurs. 
 The consideration described in paragraphs (a) through (e) of this Section 1.02
is collectively referred to as the “CSR Consideration.” 
 Section 1.03    Ongoing Obligations

 Effective as of the date hereof and immediately following the effective time of the Merger, on the terms and subject to the conditions set
forth herein, Endo does hereby: 
  

 3 

 (a) accept and assume the Company’s obligation under the CSR Agreement to provide the CSR
Consideration, and 
 (b) agree to perform and observe each and every covenant, condition, obligation and liability under the CSR Agreement
to be performed and observed by the Company. 
 ARTICLE 2 
 MISCELLANEOUS 
 Section 2.01    Effectiveness 
 This Supplemental Agreement shall become effective as of the Effective Time (as defined in the Merger Agreement) of the Merger. 
 Section 2.02    Effect of Supplemental Agreement 
 (a)    On the date hereof, the CSR Agreement shall be supplemented and amended in accordance herewith, and this Supplemental
Agreement shall form part of the CSR Agreement for all purposes, and the Holder of every CSR heretofore or hereafter authenticated and delivered under the CSR Agreement shall be bound thereby. 
 (b)    This Supplemental Agreement shall be deemed to be incorporated in, and made a part of, the CSR Agreement. The CSR Agreement,
as amended and supplemented by this Supplemental Agreement, shall be read, taken and construed as one and the same instrument and all provisions in the CSR Agreement shall remain in full force and effect in accordance with the terms thereof and as
amended and supplemented by this Supplemental Agreement. 
 Section 2.03    Severability 
 In case any one or more of the provisions contained in this Supplemental Agreement shall for any reason be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Supplemental Agreement, but this Supplemental Agreement shall be construed as if such invalid, illegal or unenforceable provision had never
been contained herein. 
 Section 2.04    Counterparts 
 This Supplemental Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an
original and all such counterparts shall together constitute but one and the same agreement. 
  

 4 

 Section 2.05    Notices 
 Any notice or demand authorized by this Supplemental Agreement or the CSR Agreement to be given or made by the Rights Agent or by any Holder to or on
Endo or the Company, or any notice pursuant to this Supplemental Agreement or the CSR Agreement to be given by the Company or by any Holder(s) to the Rights Agent, shall be sufficiently given when received by Endo or the Company or the Rights Agent
at their respective offices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given if delivered personally, sent via electronic mail (receipt confirmed), facsimile (receipt
confirmed) or sent by a nationally recognized overnight courier (providing proof of delivery) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): 
 To Endo or the Company: 
 Endo
Pharmaceuticals Holdings Inc. 
 100 Endo Boulevard 
 Chadds Ford, PA 19317 
 Fax No.: (610) 558-9864 
 Attention: Caroline B. Manogue, Esq. 
 and
with a copy to: 
 Skadden, Arps, Slate, Meagher & Flom LLP 
 Four Times Square 
 New York, New York
10036-6522 
 Fax No: (212) 735-2000 
 Attention: Eileen T. Nugent, Esq. 
 To the Rights Agent: 
 American Stock Transfer & Trust Company 
 6201 15th Avenue, 2nd Floor 
 Brooklyn, NY 11219 
 Fax: 718-921-8310 
 Attention: Marianela Patterson 
 Section 2.06    Rights Agent 
 In entering into this Supplemental Agreement, the Rights Agent shall be entitled to the benefit of every provision of the CSR Agreement relating to the conduct or affecting the liability of or affording protection to
the Rights Agent, whether or not elsewhere herein so provided. 
  

 5 

 Section 2.07    Beneficiaries 
 All covenants and provisions of this Supplemental Agreement by or for the benefit of the Company, the Rights Agent, Endo or any Holder shall bind and
inure to the benefit of their respective successors, assigns, heirs and personal representatives. Nothing in this Supplemental Agreement shall be construed to give to any person or corporation other than the Company, the Rights Agent, Endo and the
Holders any legal or equitable right, remedy or claim under this Supplemental Agreement; but this Supplemental Agreement shall be for the sole and exclusive benefit of the Company, the Rights Agent, Endo and the Holders 
 Section 2.08    Governing Law 
 THIS SUPPLEMENTAL AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE PRINCIPLES OF CONFLICTS OF LAW
THEREOF. 
 [Signatures on following page] 
  

 6 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Agreement to be duly executed as of
the day and year first above written. 
  

			
	INDEVUS PHARMACEUTICALS, INC.
		
	By:	 	/S/ CAROLINE B. MANOGUE
		 	 Name: Caroline B. Manogue
 Title:
Secretary

		 	
	ENDO PHARMACEUTICALS HOLDING INC.
		
	By:	 	/S/ CAROLINE B. MANOGUE
		 	 Name: Caroline B. Manogue
 Title: Executive Vice
President, Chief Legal Officer and Secretary

		 	
	AMERICAN STOCK TRANSFER & TRUST COMPANY, as Rights Agent
		
	By:	 	/S/ ISAAC FREILICH
		 	 Name: Isaac Freilich
 Title: VP

 [Signature Page for Supplemental Stent Contingent Stock Rights Agreement]Supplemental Supprelin CSR Agreement

 Exhibit 10.3 
 SUPPLEMENTAL SUPPRELIN CONTINGENT STOCK RIGHTS AGREEMENT 
 THIS SUPPLEMENTAL SUPPRELIN CONTINGENT
STOCK RIGHTS AGREEMENT (this “Supplemental Agreement”), dated as of March 23, 2009, is entered into by and among Indevus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Endo Pharmaceuticals Holdings
Inc., a Delaware corporation (“Endo”) and American Stock Transfer & Trust Company, as rights agent (the “Rights Agent”). 
 WHEREAS, the Company and the Rights Agent are parties to a Supprelin Contingent Stock Right Agreement, dated as of April 17, 2007 (the “CSR Agreement”), pursuant to which the Company and the
Rights Agent made certain agreements with respect to certain contingent stock rights issued by the Company in connection with its acquisition of Valera Pharmaceuticals, Inc. (each such contingent stock right, a “CSR” and
collectively, the “CSRs”). Capitalized terms used herein and not defined herein have the meanings ascribed to such terms in the CSR Agreement; 
 WHEREAS, pursuant to Section 12(b) of the CSR Agreement, upon the merger of the Company with or into another corporation, there shall thereafter be deliverable upon conversion of any CSR in accordance with the
terms of the CSR Agreement the number of shares of stock or other securities, property or cash to which a holder of the number of shares of Indevus Common Stock that would otherwise have been deliverable upon the conversion of such CSR would have
been entitled upon such merger if such CSR had been converted in full immediately prior to such merger; 
 WHEREAS, on January 5, 2009,
the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Endo and BTB Purchaser Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Endo, pursuant to which,
among other things, Merger Sub will be merged (the “Merger”) with and into the Company, with the Company continuing as the surviving corporation; 
 WHEREAS, in connection with the transactions contemplated by the Merger Agreement, Endo and American Stock Transfer & Trust Company, as paying agent, have entered into the Nebido Cash Consideration Agreement
and the Octreotide Cash Consideration Agreement, each dated as of February 23, 2009 (respectively, the “Nebido Cash Consideration Agreement” and the “Octreotide Cash Consideration Agreement”), pursuant to
which, upon the occurrence of certain regulatory and commercial milestones, Endo will make certain contingent cash consideration payments to former holders of Indevus Common Stock; 
 WHEREAS, pursuant to the Merger, the common stock of the Company shall be canceled and converted into the right to receive $4.50 per share, net in cash,
plus contractual rights to receive up to (1) $2.00 per share in contingent cash consideration payments pursuant to the Nebido Cash Consideration Agreement and (2) $1.00 per share in contingent cash consideration payments pursuant to the
Octreotide Cash Consideration Agreement; 

 WHEREAS, Section 12(c) of the CSR Agreement provides that a successor corporation to the Company
shall expressly assume certain obligations of the Company pursuant to a supplemental contingent stock rights agreement; 
 WHEREAS, pursuant
to Section 12(b) of the CSR Agreement, the board of directors of the Company has determined, in good faith, that the adjustment to the consideration payable pursuant to the CSRs set forth in Section 1.01(b) below is appropriate, which
determination has been made in a duly adopted resolution certified by the Secretary or Assistant Secretary of the Company; 
 WHEREAS, the
execution and delivery of this Supplemental Agreement has been duly authorized by each of the parties hereto and all conditions and requirements necessary to make this Supplemental Agreement a valid and binding agreement have been duly performed and
complied with; and 
 WHEREAS, pursuant to Section 6.14(a) of the Merger Agreement, this Supplemental Agreement is being executed and
delivered prior to the effectiveness of the Merger. 
 NOW, THEREFORE, in consideration of the premises set forth herein and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is mutually covenanted and agreed, for the equal and proportionate benefit of all registered Holders, as follows: 
 ARTICLE 1 
 COVENANTS 

 Section 1.01    Effect of Merger 
 Each of Endo and the Company hereby agree and instruct the Rights Agent that the transactions contemplated by the Merger Agreement, including without limitation, the Merger and the cancellation and conversion of the
Company’s common stock pursuant to Section 3.1(a) of the Merger Agreement, shall be deemed to be a “Reorganization” within the meaning of Section 12(b) of the CSR Agreement. 
 Section 1.02    CSR Consideration 
 Each of Endo and the Company hereby agree and instruct the Rights Agent that, notwithstanding the terms of Section 7(b) of the CSR Agreement and subject to the other terms of the CSR Agreement, each CSR shall
become convertible and shall entitle the Holder thereof, upon 

  

 2 

 
satisfaction of the procedures described in Section 8 of the CSR Agreement, until 5:00 p.m., New York City time, on the Termination Date, to receive
from Endo or the Company only: 
 (a)    an amount in cash equal to the product of (x) $4.50 and (y) 0.141 (the
“Exchange Ratio”), 
 (b)    the contractual right, subject to the terms of the Octreotide Cash
Consideration Agreement, to receive an amount in cash equal to the product of (x) $1.00 and (y) the Exchange Ratio, in the case that the Approval Milestone Date (as defined in the Octreotide Cash Consideration Agreement) occurs on or
before February 23, 2013, 
 (c)    the contractual right,
subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $2.00 and (y) the Exchange Ratio, in the case that the Approval with Label Milestone Date (as defined in the
NEBIDO® Cash Consideration Agreement) occurs on or before February 23, 2012, 
 (d)    the contractual right, subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $1.00 and (y) the Exchange Ratio, in the case that the
Approval without Label Milestone Date (as defined in the Nebido Cash Consideration Agreement) occurs on or before February 23, 2012, and 
 (e)    the contractual right, subject to the terms of the Nebido Cash Consideration Agreement, to receive an amount in cash equal to the product of (x) $1.00 and (y) the Exchange Ratio, in the case that the Net
Sales Milestone Date (as defined in the Nebido Cash Consideration Agreement) occurs. 
 The consideration described in paragraphs
(a) through (e) of this Section 1.02 is collectively referred to as the “CSR Consideration.” 
 Section
1.03    Ongoing Obligations 
 Effective as of the date hereof and immediately following the effective time of the
Merger, on the terms and subject to the conditions set forth herein, Endo does hereby: 
 (a)    accept and assume the
Company’s obligation under the CSR Agreement to provide the CSR Consideration, and 
 (b)    agree to perform and
observe each and every covenant, condition, obligation and liability under the CSR Agreement to be performed and observed by the Company. 
  

 3 

 ARTICLE 2 
 MISCELLANEOUS 
 Section 2.01    Effectiveness 
 This Supplemental Agreement shall become effective as of the Effective Time (as defined in the Merger Agreement) of the Merger. 
 Section 2.02    Effect of Supplemental Agreement 
 (a)    On the date hereof, the CSR Agreement shall be supplemented and amended in accordance herewith, and this Supplemental
Agreement shall form part of the CSR Agreement for all purposes, and the Holder of every CSR heretofore or hereafter authenticated and delivered under the CSR Agreement shall be bound thereby. 
 (b)    This Supplemental Agreement shall be deemed to be incorporated in, and made a part of, the CSR Agreement. The CSR Agreement,
as amended and supplemented by this Supplemental Agreement, shall be read, taken and construed as one and the same instrument and all provisions in the CSR Agreement shall remain in full force and effect in accordance with the terms thereof and as
amended and supplemented by this Supplemental Agreement. 
 Section 2.03    Severability 
 In case any one or more of the provisions contained in this Supplemental Agreement shall for any reason be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Supplemental Agreement, but this Supplemental Agreement shall be construed as if such invalid, illegal or unenforceable provision had never
been contained herein. 
 Section 2.04    Counterparts 
 This Supplemental Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an
original and all such counterparts shall together constitute but one and the same agreement. 
 Section
2.05    Notices 
 Any notice or demand authorized by this Supplemental Agreement or the CSR Agreement to be given or
made by the Rights Agent or by any Holder to or on Endo or the Company, or any notice pursuant to this Supplemental Agreement or the CSR Agreement to be given by the Company or by any Holder(s) to the Rights Agent, shall be sufficiently given when
received by Endo or the Company or the Rights Agent at their respective offices. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given if 

  

 4 

 
delivered personally, sent via electronic mail (receipt confirmed), facsimile (receipt confirmed) or sent by a nationally recognized overnight courier
(providing proof of delivery) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice): 
 To Endo or the Company: 
 Endo Pharmaceuticals Holdings Inc. 
 100 Endo Boulevard 
 Chadds Ford, PA 19317

 Fax No.: (610) 558-9864 
 Attention: Caroline B. Manogue, Esq. 
 and with a copy to: 
 Skadden, Arps, Slate, Meagher & Flom LLP 
 Four Times Square 
 New York, New York 10036-6522 
 Fax No: (212) 735-2000 
 Attention: Eileen T. Nugent, Esq. 
 To the Rights Agent: 
 American Stock
Transfer & Trust Company 
 6201 15th Avenue, 2nd Floor 
 Brooklyn, NY 11219 
 Fax: 718-921-8310 
 Attention: Marianela Patterson 
 Section
2.06    Rights Agent 
 In entering into this Supplemental Agreement, the Rights Agent shall be entitled to the
benefit of every provision of the CSR Agreement relating to the conduct or affecting the liability of or affording protection to the Rights Agent, whether or not elsewhere herein so provided. 
 Section 2.07    Beneficiaries 
 All covenants and provisions of this Supplemental Agreement by or for the benefit of the Company, the Rights Agent, Endo or any Holder shall bind and inure to the benefit of their respective successors, assigns, heirs
and personal representatives. Nothing in this Supplemental Agreement shall be construed to give to any person or corporation other than the Company, the Rights 

  

 5 

 
Agent, Endo and the Holders any legal or equitable right, remedy or claim under this Supplemental Agreement; but this Supplemental Agreement shall be for the
sole and exclusive benefit of the Company, the Rights Agent, Endo and the Holders 
 Section 2.08    Governing Law

 THIS SUPPLEMENTAL AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE
LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE PRINCIPLES OF CONFLICTS OF LAW THEREOF. 
 [Signatures on following page] 
  

 6 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Agreement to be duly executed as of
the day and year first above written. 
  

			
	INDEVUS PHARMACEUTICALS, INC.
		
	By:	 	/S/    CAROLINE B. MANOGUE
		 	 Name: Caroline B. Manogue
 Title:
Secretary

		 	
	ENDO PHARMACEUTICALS HOLDING INC.
		
	By:	 	/S/    CAROLINE B. MANOGUE
		 	 Name: Caroline B. Manogue
 Title: Executive Vice
President, Chief Legal Officer and Secretary

		 	
	AMERICAN STOCK TRANSFER & TRUST COMPANY, as Rights Agent
		
	By:	 	/S/    ISAAC FREILICH
		 	 Name: Isaac Freilich
 Title: VP

 [Signature Page for Supplemental Supprelin Contingent Stock Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]